These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34157482)

  • 1. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
    Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
    EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
    Aziz-Bose R; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.
    Nonnenbroich LF; Bouchal SM; Millesi E; Rechberger JS; Khatua S; Daniels DJ
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.
    Schuelke MR; Wongthida P; Thompson J; Kottke T; Driscoll CB; Huff AL; Shim KG; Coffey M; Pulido J; Evgin L; Vile RG
    J Immunother Cancer; 2019 Jul; 7(1):188. PubMed ID: 31315671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
    J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
    Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
    Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
    Ausejo-Mauleon I; Labiano S; de la Nava D; Laspidea V; Zalacain M; Marrodán L; García-Moure M; González-Huarriz M; Hervás-Corpión I; Dhandapani L; Vicent S; Collantes M; Peñuelas I; Becher OJ; Filbin MG; Jiang L; Labelle J; de Biagi-Junior CAO; Nazarian J; Laternser S; Phoenix TN; van der Lugt J; Kranendonk M; Hoogendijk R; Mueller S; De Andrea C; Anderson AC; Guruceaga E; Koschmann C; Yadav VN; Gállego Pérez-Larraya J; Patiño-García A; Pastor F; Alonso MM
    Cancer Cell; 2023 Nov; 41(11):1911-1926.e8. PubMed ID: 37802053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
    Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
    Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse midline glioma: review of epigenetics.
    Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
    J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy approaches for the treatment of diffuse midline gliomas.
    Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
    Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.
    Guo Y; Li Z; Parsels LA; Wang Z; Parsels JD; Dalvi A; The S; Hu N; Valvo VM; Doherty R; Peterson E; Wang X; Venkataraman S; Agnihotri S; Venneti S; Wahl DR; Green MD; Lawrence TS; Koschmann C; Morgan MA; Zhang Q
    bioRxiv; 2024 Aug; ():. PubMed ID: 39253432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma.
    Mbah NE; Myers AL; Sajjakulnukit P; Chung C; Thompson JK; Hong HS; Giza H; Dang D; Nwosu ZC; Shan M; Sweha SR; Maydan DD; Chen B; Zhang L; Magnuson B; Zhu Z; Radyk M; Lavoie B; Yadav VN; Koo I; Patterson AD; Wahl DR; Franchi L; Agnihotri S; Koschmann CJ; Venneti S; Lyssiotis CA
    Nat Commun; 2024 Oct; 15(1):8983. PubMed ID: 39419964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T cell therapies for diffuse midline glioma.
    Thomas BC; Staudt DE; Douglas AM; Monje M; Vitanza NA; Dun MD
    Trends Cancer; 2023 Oct; 9(10):791-804. PubMed ID: 37541803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma.
    du Chatinier A; Meel MH; Das AI; Metselaar DS; Waranecki P; Bugiani M; Breur M; Simonds EF; Lu ED; Weiss WA; Garcia Vallejo JJ; Hoving EW; Phoenix TN; Hulleman E
    Neurooncol Adv; 2022; 4(1):vdac079. PubMed ID: 35733514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.
    Das AK; Sinha M; Singh SK; Chaudhary A; Boro AK; Agrawal M; Bhardwaj S; Kishore S; Kumari K
    Acta Neurol Belg; 2024 Aug; 124(4):1251-1261. PubMed ID: 38669002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.